WELLS FARGO & COMPANY/MN

Position in LGVN — Longeveron Inc.

CIK 72971 SAN FRANCISCO, CA

Position in LGVN

as of Jun 30, 2026 · filed Aug 14, 2026 Compact

Position Value

$703

-$197 QoQ

Shares Held

1,000

+115.5% QoQ

Ownership

0.003%

of shares outstanding

% of Portfolio

0.00%

of 13F equity value

Holder Rank

#33

of 39 holders

Holding Since

Mar 2021

16 quarters on record

Voting authority Sole 100% Shared 0% None 0%

Healthcare · as of Jun 30, 2026

WELLS FARGO & COMPANY/MN holds $1,567,775,044 across 417 Biotechnology names. LGVN ranks #368 (0.0% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	VRTX	Vertex Pharmaceuticals Inc / Ma	749,528	$372,313,040
2	HALO	Halozyme Therapeutics, Inc.	1,390,428	$108,828,797
3	ALNY	Alnylam Pharmaceuticals, Inc.	310,047	$93,333,446
4	REGN	Regeneron Pharmaceuticals, Inc.	140,802	$87,795,677
5	EXEL	Exelixis, Inc.	717,840	$39,057,673
6	RVMD	Revolution Medicines, Inc.	178,780	$33,481,916
7	ARGX	Argenx SE	34,453	$31,964,458
8	INCY	Incyte Corp	255,064	$28,914,053

16 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$703	1,000	+115.5%	Shares	Defined	2026-08-14
2024-09-30	$900	464	0.0%	Shares	Defined	2024-11-13
2024-06-30	$747	464	-1.5%	Shares	Defined	2024-08-13
2024-03-31	$1,529	471	-90.0%	Shares	Defined	2024-05-10
2023-12-31	$6,383	4,694	+3252.9%	Shares	Defined	2024-02-09
2023-09-30	$327	140	+241.5%	Shares	Defined	2023-11-13
2023-06-30	$138	41	+7.9%	Shares	Defined	2023-08-15
2023-03-31	$101	38	+2.7%	Shares	Defined	2023-05-12
2022-12-31	$119	37	+2.8%	Shares	Defined	2023-02-13
2022-09-30	$133	36	+12.5%	Shares	Defined	2022-11-14
2022-06-30	$189	32	+14.3%	Shares	Defined	2022-08-12
2022-03-31	$386	28	+47.4%	Shares	Defined	2022-05-16
2021-12-31	$229	19	+5.6%	Shares	Defined	2022-02-14
2021-09-30	$63	18	-5.3%	Shares	Defined	2021-11-15
2021-06-30	$154	19	+11.8%	Shares	Defined	2021-08-16
2021-03-31	$112	17	—	Shares	Defined	2021-05-13
No filing history on record for this holder in this stock.